I. Benattia

1.0k total citations
18 papers, 678 citations indexed

About

I. Benattia is a scholar working on Psychiatry and Mental health, Clinical Psychology and Pharmacology. According to data from OpenAlex, I. Benattia has authored 18 papers receiving a total of 678 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Psychiatry and Mental health, 6 papers in Clinical Psychology and 5 papers in Pharmacology. Recurrent topics in I. Benattia's work include Treatment of Major Depression (5 papers), Schizophrenia research and treatment (5 papers) and Attention Deficit Hyperactivity Disorder (3 papers). I. Benattia is often cited by papers focused on Treatment of Major Depression (5 papers), Schizophrenia research and treatment (5 papers) and Attention Deficit Hyperactivity Disorder (3 papers). I. Benattia collaborates with scholars based in United States, South Africa and France. I. Benattia's co-authors include Jeff Musgnung, Jonathan Davidson, Michael E. Thase, Charles B. Nemeroff, Richard Entsuah, Mark A. Demitrack, Saeed Ahmed, David S. Baldwin, Dan J. Stein and Ron Pedersen and has published in prestigious journals such as Biological Psychiatry, Psychopharmacology and Schizophrenia Research.

In The Last Decade

I. Benattia

18 papers receiving 625 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
I. Benattia United States 10 294 263 247 107 61 18 678
Stephanie C. Koke United States 12 345 1.2× 289 1.1× 183 0.7× 133 1.2× 48 0.8× 19 795
Paolo Olgiati Italy 16 282 1.0× 199 0.8× 335 1.4× 138 1.3× 74 1.2× 41 886
David N. Osser United States 17 235 0.8× 226 0.9× 431 1.7× 122 1.1× 39 0.6× 51 775
W. Alexander Morton United States 10 119 0.4× 110 0.4× 331 1.3× 60 0.6× 116 1.9× 13 595
Vera Folnegović-Šmalc Croatia 18 247 0.8× 96 0.4× 296 1.2× 19 0.2× 71 1.2× 72 866
Rajesh R. Tampi United States 16 170 0.6× 152 0.6× 366 1.5× 45 0.4× 50 0.8× 56 851
Gary M. Levin United States 15 154 0.5× 153 0.6× 399 1.6× 54 0.5× 124 2.0× 33 794
Francis M. Mondimore United States 14 242 0.8× 99 0.4× 227 0.9× 93 0.9× 41 0.7× 20 695
Alessandra Signoretti Italy 7 100 0.3× 319 1.2× 306 1.2× 155 1.4× 78 1.3× 9 730
Jan Fawcett United States 13 133 0.5× 287 1.1× 234 0.9× 164 1.5× 71 1.2× 16 739

Countries citing papers authored by I. Benattia

Since Specialization
Citations

This map shows the geographic impact of I. Benattia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Benattia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Benattia more than expected).

Fields of papers citing papers by I. Benattia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Benattia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Benattia. The network helps show where I. Benattia may publish in the future.

Co-authorship network of co-authors of I. Benattia

This figure shows the co-authorship network connecting the top 25 collaborators of I. Benattia. A scholar is included among the top collaborators of I. Benattia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Benattia. I. Benattia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Smith, Meredith Y., et al.. (2017). Structured Benefit-Risk Assessment Across the Product Lifecycle: Practical Considerations. Therapeutic Innovation & Regulatory Science. 51(4). 501–508. 11 indexed citations
2.
Benattia, I., et al.. (2016). The Patient’s Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization. Drug Safety. 39(9). 779–785. 22 indexed citations
3.
Nemeroff, Charles B., et al.. (2010). Comprehensive Analysis of Remission (COMPARE) with Venlafaxine versus SSRIs. FOCUS The Journal of Lifelong Learning in Psychiatry. 8(4). 592–604. 66 indexed citations
4.
Davidson, Jonathan, David S. Baldwin, Dan J. Stein, et al.. (2008). Effects of venlafaxine extended release on resilience in posttraumatic stress disorder: an item analysis of the Connor–Davidson Resilience Scale. International Clinical Psychopharmacology. 23(5). 299–303. 36 indexed citations
5.
Nemeroff, Charles B., et al.. (2007). Comprehensive Analysis of Remission (COMPARE) with Venlafaxine versus SSRIs. Biological Psychiatry. 63(4). 424–434. 104 indexed citations
6.
Davidson, Jonathan, David S. Baldwin, Dan J. Stein, et al.. (2006). Treatment of Posttraumatic Stress Disorder With Venlafaxine Extended Release. Archives of General Psychiatry. 63(10). 1158–1158. 148 indexed citations
7.
Davidson, Jonathan, Barbara O. Rothbaum, Phebe Tucker, et al.. (2006). Venlafaxine Extended Release in Posttraumatic Stress Disorder. Journal of Clinical Psychopharmacology. 26(3). 259–267. 105 indexed citations
8.
Kroenke, Kurt, et al.. (2006). Venlafaxine Extended Release in the Short-Term Treatment of Depressed and Anxious Primary Care Patients With Multisomatoform Disorder. The Journal of Clinical Psychiatry. 67(1). 72–80. 53 indexed citations
9.
10.
Addington, Donald, et al.. (2004). Efficacy and Tolerability of Ziprasidone Versus Risperidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder. The Journal of Clinical Psychiatry. 65(12). 1624–1633. 66 indexed citations
11.
Benattia, I., et al.. (2003). Ziprasidone versus risperidone in schizophrenia: An eight-week, double-blind trial with forty four-week continuation. Schizophrenia Research. 60(1). 273–273. 3 indexed citations
12.
Brook, S., et al.. (2003). Sequential IM/oral ziprasidone versus haloperidol in schizophrenia with anxiety. Schizophrenia Research. 60(1). 275–275. 2 indexed citations
13.
Daniel, D.G., S. Brook, & I. Benattia. (2003). P.2.048 Efficacy of intramuscular ziprasidone without adjunctive benzodiazepines. European Neuropsychopharmacology. 13. S299–S300. 3 indexed citations
14.
Addington, Donald, et al.. (2003). P.2.046 Ziprasidone versus risperidone in schizophrenia: 52 weeks' comparative data. European Neuropsychopharmacology. 13. S299–S299. 3 indexed citations
15.
Zimbroff, Dan, S. Brook, & I. Benattia. (2002). Safety and tolerability of IM ziprasidone: Review of clinical trial data. European Neuropsychopharmacology. 12. 294–294. 1 indexed citations
16.
Addington, Donald, Christos Pantelis, & I. Benattia. (2002). Ziprasidone vs risperidone in schizophrenia: An 8-week, double-blind trial. European Neuropsychopharmacology. 12. 314–314. 4 indexed citations
17.
Spina, Edoardo, et al.. (2002). Ziprasidone vs amisulpride for negative symptoms of schizophrenia. European Neuropsychopharmacology. 12. 313–313. 3 indexed citations
18.
Benattia, I., et al.. (1999). [What is the meaning of "stabilization" in schizophrenic patients?].. PubMed. 24(4). 331–6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stephanie C. Koke Breakdown of academic impact, for papers by Paolo Olgiati Breakdown of academic impact, for papers by David N. Osser Breakdown of academic impact, for papers by W. Alexander Morton Breakdown of academic impact, for papers by Vera Folnegović-Šmalc Breakdown of academic impact, for papers by Rajesh R. Tampi Breakdown of academic impact, for papers by Gary M. Levin Breakdown of academic impact, for papers by Francis M. Mondimore Breakdown of academic impact, for papers by Alessandra Signoretti Breakdown of academic impact, for papers by Jan Fawcett
Rankless by CCL
2026